Dosing & Uses
Dosage Forms & Strengths
ophthalmic intracanalicular insert
- 0.4mg
Ocular Pain and Inflammation
Bioresorbable hydrogel-based drug-eluting intracanalicular depot indicated for ocular pain and inflammation following ophthalmic surgery
Insert in lower lacrimal punctum into the canaliculus; a single insert releases 0.4 mg for up to 30 days following insertion
Insert is resorbable and does not require removal; perform saline irrigation or manual expression to remove the insert if necessary
Ocular Itching Associated with Allergic Conjunctivitis
Indicated for ocular itching associated with allergic conjunctivitis
Insert in lower lacrimal punctum into the canaliculus; a single insert releases 0.4 mg for up to 30 days following insertion
Insert is resorbable and does not require removal; perform saline irrigation or manual expression to remove the insert if necessary
Safety and efficacy not established
Adverse Effects
1-10%
Anterior chamber inflammation including iritis and iridocyclitis (9%)
Increased intraocular pressure (IOP) (5%)
Visual acuity reduced (2%)
Eye pain (1%)
Cystoid macular edema (1%)
Corneal edema (1%)
Conjunctival hyperemia (1%)
Headache (1%)
Warnings
Contraindications
Active corneal, conjunctival, or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye; dacryocystitis
Cautions
The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining; if signs and symptoms fail to improve after 2 days, the patient should be re-evaluated
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity, and defects in fields of vision; caution if used in the presence of glaucoma; monitor IOP
Corticosteroids may suppress immune response and increase risk for secondary ocular infections; may also mask infection and enhance existing infection
Ocular corticosteroids may prolong viral eye infections and exacerbate severity
Consider fungal invasion with any persistent corneal ulceration while using ocular corticosteroids
Use after cataract surgery may delay healing and increase bleb formation incidence
Pregnancy
Pregnancy
Data are not available regarding use in pregnant women
Animal data
- Topical ocular dexamethasone to pregnant mice and rabbits during organogenesis produced embryofetal lethality, cleft palate, and multiple visceral malformations
- In mice, topical ocular administration of 0.15% dexamethasone (0.75 mg/kg/day) on gestational days 10-13 produced embryofetal lethality and a high incidence of cleft palate; 0.75 mg/kg/day in mice is ~5x the entire dose of dexamethasone in the Dextenza product (based on body surface)
- In rabbits, topical ocular administration of 0.1% dexamethasone throughout organogenesis (0.36 mg/day, on gestational day 6, then 0.24 mg/day on gestational days 7-18) produced intestinal anomalies, intestinal aplasia, gastroschisis, and hypoplastic kidneys; 0.24 mg/day is ~6x the entire dose of dexamethasone in the Dextenza product (based on body surface)
Lactation
Unknown if distributed in human breast milk
Systemically administered corticosteroids appear in human milk and could suppress growth and interfere with endogenous corticosteroid production; however, systemic concentration of dexamethasone following administration of Dextenza is low
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Corticosteroid; decreases postoperative ocular pain by suppressing inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells
Absorption
Low plasma concentrations were detectable (>50 pg/mL, lower limit of quantification) in 11% of samples (21 of 189), and ranged from 0.05-0.81 ng/mL
Administration
Intracanalicular Administration
For single intracanalicular use only
Do not use if pouch damaged or opened; do not resterilize
Instructions
- Carefully remove foam carrier and transfer to a clean and dry area
- If necessary, dilate punctum with an ophthalmic dilator; do not perforate the canaliculus during dilation or insertion of dexamethasone; if perforation occurs, do not insert dexamethasone
- After drying punctal area, use blunt (nontoothed) forceps to grasp dexamethasone and insert into the lower lacrimal canaliculus; it should be placed just below the punctal opening; excessively squeezing the insert may cause deformation
- To aid hydration, instill 1-2 drops of balanced salt solution into punctum; insert hydrates quickly upon contact with moisture
- If dexamethasone begins to hydrate before fully inserted, discard product and use a new dexamethasone
- Inserts can be visualized when illuminated by a blue light source (eg, slit lamp or hand held blue light) with yellow filter
Storage
Store refrigerated, between 2-8°C (36-46°F)
Do not freeze
Protect from light; keep in package until use
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.